In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelics.
| Ticker |
GHRS
|
| CIK | 0001855129 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&AA potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelics. Weekly Roundup on the Cannabis Sector & Psychedelic SectorKey Takeaways; Cannabis Sector Cannara Biotech secured 5 vape cartridge listings in Québec market launch Cresco Labs exited California market amid industry challenges and strategic refocus MTL Cannabis announced a “new era” with record revenue and profit in 2025 Key Takeaways; Psychedelic Sector GH Research nears resolution with FDA, reporting promising long-term results in depression […] GH Research Announces Global Pivotal Program Plans and Further Development UpdatesEngagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suicidal ideation or behaviorGlobal pivotal program initiation on track for 2026 DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clin Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of ScheduleGH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New Drug/IND Application for GH001. The submission was made ahead of schedule, which showed the company’s commitment to […] |